Video

Vladimir Maletic, MD: How Early Life Adversity Affects Mental Health

Author(s):

Parental rejection, abandonment, physical and sexual abuse double the victim's rates of depression, inflammation, metabolic disorders and chronic medical illnesses.

Vladimir Maletic, MD:

Early life adversity is a major factor in treatment of psychiatric disorders. Not only does early life adversity increase the risk of developing a number of psychiatric conditions, primarily major depressive disorder, it very much influences treatment outcomes.

In a large study that was conducted in New Zealand, with several thousand participants, they looked at, prospectively measured early life adversity and what kind of impact may it have on psychiatric disorders and overall health.

What they found is that early life adversity, and it was very precisely defined -- parental rejection, parental abandonment, sexual trauma, physical abuse, -- so this was all collectively documented occurring between the ages 3 and 11.

So individuals who had 0 traumatic events, versus the ones who had 2 or more had significant difference in terms of their depression rates 32 years later.

Individuals who have suffered more than 2 adverse early life events had double the rates of depression, but interestingly enough they also had double the rates of inflammation as measured high sensitivity, CRP scores above 3 -- they had double the rates of metabolic disorders, and they had double the risk of developing 2 or more chronic medical illnesses.

So early life adversity is a significant prognosticator of future occurrences of major depressive disorder.

More from the 30th Annual Psych Congress in New Orleans, LA.

Related Videos
Gregory Mattingly, MD I St. Charles Psychiatric Associates
John Kane, MD | Credit: Northwell Health
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Sibgha Zaheer, MD: Determining Washout Period With Fitusiran, Emicizumab Transition for Hemophilia
Pavan K. (Tem) Bendapudi, MD: Large-Scale Analyses Elucidate Genetic Risk of Thrombosis
Seema Rani, MD: Examining Sleep Health in Youth With SCD
Daniel Wang: A More Appropriate Ferritin Threshold is Cost-Effective for Iron Deficiency Screening
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
© 2025 MJH Life Sciences

All rights reserved.